IRIDEX today announced the release of data from a study of its MicroPulse® P3 device (powered by the same proprietary MicroPulse laser technology in the IRIDEX Cyclo G6TM glaucoma laser system) demonstrating that the device was safe and efficacious for the acute reduction of intraocular pressure (IOP) in patients with refractory glaucoma. The data was originally presented at the European Glaucoma Society (EGS) Meeting on June 19-22, 2016, in Prague, Czech Republic.

MicroPulse is a tissue-sparing laser delivery therapy that works by electronically “chopping” the laser emission into trains of microsecond pulses. This enhances the physician’s ability to more precisely control the laser effects on target tissues, offering the potential for ocular treatment with less collateral effects than conventional laser treatments.